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Osteoarthritis (OA) is a common complaint that affects millions of people worldwide. 
As there is no cure for OA, drug treatment is the main form of management. This can 
be achieved through the use of analgesics and anti-inflammatory drugs such as the 
NSAID diclofenac sodium. The chronic use of diclofenac sodium can lead to adverse 
gastrointestinal problems. The use of a topical formulation of diclofenac sodium aims 
to reduce this problem. Evidence from four randomized controlled trails of the 
efficacy and safety of topical diclofenac sodium as a method of pain relief for the 
treatment of OA of the knee is presented and discussed. Findings imply that topical 
diclofenac sodium is an efficacious and safe method of pain control in patients with 









Osteoarthritis (OA) is a common degenerative joint disorder that affects people from 
third decade of life and progresses with advancing age (Altman, 2004, Hillaire, 2006). 
In the US, it is estimated that between 21 and 40 million people suffer from OA with 
at least 70% to 90% of the population suffering from degenerative changes involving 
at least one joint (Arthritis Foundation, 1999, Hillaire 2006, Oddis, 1996). The 
prevalence of OA increases with the ageing process (Lawrence & Hochberg, 1989). 
Gender appears to influence the onset of OA, where women are twice as likely to 
develop OA in the hands and knees compared to age-matched men (Solomon, 2001).    
 
OA was once referred to as the ‘wear and tear’ disorder due to the progressive loss of 
articular cartilage from joints and underlying bone (Felson et al., 2000), often leading 
to joint inflammation. Weight bearing joints are commonly affected (Health Notes, 
2005) but the hands, spine, ankles, wrists, elbows and shoulders can also be affected 
(Hillaire, 2006).  The characteristic symptoms include; joint pain, joint instability, 
loss of function, morning stiffness lasting up to 30 minutes, pain with motion and 
limitation of range of motions, crepitus with motion and bony enlargement in affected 
joints (Hillaire, 2006). 
 
Currently there is no cure for OA. Management options involve both non-
pharmacological and pharmacological treatment forms. Non-pharmacological 
management includes the following; patient education about diet, encouraging weight 
loss and exercise, social support, assistive devices for ambulation, appropriate 
footwear, occupational therapy, joint protection and devices to assist activities of 
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daily living (Hillaire, 2006). Even though these forms of treatment are available, it is 
established that pain restricts mobility and willingness and ability to undertake any 
form of physical activity. Inactivity can hasten disability and exacerbate joint pain. 
For these reasons pharmacological treatment is viewed as the mainstay of treatment. 
Analgesics such as paracetamol and tramadol and antinflammatory agents such as 
Non-Steroidal Anti-inflammatory agents (NSAIDs), cyclooxygenase -2-(COX-2) 
specific inhibitors such as celecoxib, intra-articular glucocorticoids and hyaluronate 
are the main forms of treatment.  The NSAIDs represent the largest range of drugs 
that includes; salicylates, propionic acid substitutes such as ibuprofen and naproxen, 
acetic acid derivates such as diclofenac and indomethacin.  Oral forms of NSAIDs are 
used for patients with moderate to severe OA related pain they carry the risk of 
gastrointestinal disturbance and toxicity even at low doses (DeAngleo & Gordin, 
2004). The risk of gastrointestinal toxicity is increased in patients over the age of 65 
years, those with a history of gastrointestinal bleeding or gastric ulcer, patients 
concomitantly prescribed oral corticosteroids, anticoagulants or multiple doses of 
NSAIDs (Lichtenstein et al., 1995). Due to the added risk of developing 
gastrointestinal toxicity, patients are prescribed NSAIDs at the lowest dose possible 
and increasing the dose as tolerance develops (ACR, 2000).   
 
Oral forms of diclofenac have been compared with paracetamol (Case et al., 2003, 
Pincus et al., 2001, Pincus et al.,2005)  novel anti-inflammatory compounds (Lung et 
al., 2004), leech therapy (Michalsen et al., 2003), enzymic anti-inflammatory 
compounds (Akhtar et al., 2004). In all studies, diclofenac produced greater pain 




COX-2-specific inhibitors are appropriate for patients with moderate to severe pain 
associated with OA of the knee and hip. Numerous studies have demonstrated that 
COX-2 inhibitors are efficacious in the management of osteoarthritic symptoms 
(Fleischmann et al., 2006, McKenna et al., 2001) and can produce equivalent pain 
relief to the NSAID diclofenac (Alvarez-Soria et al., 2006,Gottesdiener et al.,2003, 
Liang & Hsu, 2003, Schnitzer et al., 2004, Zacher et al., 2003).  COX-2 inhibitors are 
less likely to produce gastrointestinal disturbances but unfortunately run the risk of 
cardiovascular complications such as stroke and cardiac arrest. This problem led to 
the withdrawal of 2 widely used COX-2-specific inhibitors, rofecoxib and valdecoxib 
from the market. This problem was the stimulus for the development of a topical 
formulation of the NSAIDs diclofenac sodium. This formulation is absorbed via the 
dermis and has low systemic availability (Brunner et al., 2005) and has markedly 
reduced gastrointestinal side effects (Evans et al., 1995). 
 
Since its development topical diclofenac has been used as an anti-inflammatory drug 
to alleviate the pain symptoms in patients with OA and researched in short-term, 2 
week studies (Cooper et al., 2004, Grace et al., 1999, Lin, et al., 2004) and compared 
to ketoprofen (Waikakul et al., 1997) and placebo (Dreiser & Tisne-Camus, 1993). 
This time duration is too short to measure therapeutic effectivness particularly as OA 
is a long-term chronic disease that requires treatment over long periods of time. In 
order to assess the efficacy and safety of use of topical NSAIDS, it was necessary to 
conduct studies over periods longer than two weeks. Studies of short duration were 
not included as they are unlikely to capture important long-term safety information 
which will be of importance for ongoing applications of gels, creams or sprays in 
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chronic conditions. This paper aims to explore the use of the topical NSAID 
diclofenac sodium in the pain management of treatment of OA of the knee. 
Method 
Papers were selected that were published from 1999 to 2006 commensurate with 
current developments in drug formulation and drug availability. Search strategy used 
included; Cochrane Library, EMBA, Pub Med., Medline, Pre-Medline to include 
access to both UK and International Research. The following web-based journals 
were also reviewed; J. Rheumatology, BMC, Muscloskeletal Journal, Canadian MA 
Journal, J. Clinical Rhuematology, Br, J. Clinical Pharmacology, Archives of Internal 
Medicine and the American J. of Medicine. Drug based information was located from 
relevant websites; virtual rheumatology centre, mayoclinic, creative consultants, 
yahoo health, medscape and wikipedia. Papers were selected that were written in 
English, studies that were of longer than 2 weeks duration were preferentially selected 
as OA is a chronic disease which involves the prolonged use of NSAIDs, safety and 
efficacy could not be assessed in periods of less than 2 weeks (Mason et al., 2004), so 
studies of short duration, less than three weeks were excluded. Studies were 
preferentially selected that used a randomized controlled trial research design 
approach with double blinding with identified selection and exclusion criteria for the 
selection of the sample. This was to ensure that the studies selected accurately 
assessed and compared treatment modalities and carefully selected their patients 
particularly those that may be sensitive to the actions of NSAIDs as this could lead to 
false results.  
 
Studies were excluded that did not use a validated pain and physical status research 
tool such as the Western Ontario and McMaster (WOMAC) osteoarthritis Index 
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questionnaire. WOMAC is a 24-item questionnaire which uses a likert subscale to 
assess pain, physical function, stiffness and assessed pain intensity.  
 
Results 
In total 5 clinical trials were identified. Each study used a randomized sampling 
approach to select patients using strict exclusion and inclusion criteria. In each study 
patients were excluded that were sensitive to NSAIDs. All studies used the validated 
Western Ontario and MacMaster Universities (WOMAC) LK3. OA index (Bellamy et 
al.  1988). The Patient Global Assessment (PGA) questionnaire was also included, 
this focuses on “how has the osteoarthritis in your study joint been over the last 48 
hours” and is also scored using a likert scale (Bellamy et al., 1988).   
 
Baer et al, (2005) used mean and standard deviation measurements to assess baseline 
flare of pain using both the WOMAC and PGA assessment questionnaires. Findings 
suggest that patients in the drug group had a 50% reduction in pain and improvements 
in responses to walking, morning stiffness and physical function and overall adequate 
pain relief compared to the control group. This response was not significantly 
different from the control group. Baer et al.,(2005) suggest that the lack of significant 
response to pain in the drug treatment group patients compared to control may be due 
to the definition of clinical success, as the mathematical assessments and the number-
needed-to-treat assessment used to see a clinical effect were equivalent to published 
studies (Osiri et al., 2003). The data suggest that the lack of therapeutic effectiveness 
to NSAIDS as a whole may result from the fact that patients who are intolerant to the 




In Baer et al, (2005) study 39% of the drug treatment group and 21% of control group 
developed dry skin. Both groups administered solutions that contained dimethyl 
sulfoxide, this compound dissolves the natural oils found in the epithelium and leads 
to dry skin. Dimethyl sulfoxide is used as the control solution and is also present in 
the drug solution where it acts as a carrier for diclofenac sodium. The safety of 
diclofenac sodium was verified by the negligible incidence (3.7%) of gastrointestinal 
side effects such as dyspepsia and abdominal pain and is lower than published 
findings with oral NSAIDs and COX-2-specific inhibitors (Tugwell et al., 2004) and 
with that of Bookman et al., (2004). 
 
In contrast, Niethard et al., (2005) found that in a short term 3 week study topical 
diclofenac was more effective than placebo in relieving the symptoms of OA of the 
knee in 238 randomly selected patients. Treatment with topical diclofenac was not 
associated with any adverse side effects. More recent, equivalent studies that 
examined the therapeutic effectiveness of topical diclofenac over a 12 week period 
reported similar findings ( Towheed, 2006).  
 
Tugwell et al. (2004) compared the use of topical diclofenac to oral diclofenac in a 
randomized sample of 622 patients with OA of the knee over a 12 week period. 
Topical diclofenac was as efficacious as the oral formulation in relieving pain, and did 
not cause any significant abnormalities in liver function, haemoglobin or creatinine 
clearance. These findings concur with those of Towheed, (2006).  Similarly, Roth et 
al., (2004) found that patients that received topical diclofenac experienced a 45.7% 
improvement in pain control. This was accompanied by improvements in physical 
function (36.7%), morning stiffness (35.1%) and pain on walking (45%). A minority 
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of patients experienced minor skin irritation; pruritus and a vesiculobullous rash were 
found.  No other adverse effects were found. These findings also concur with those of  
Bookman et al., (2004).  
 
Conclusion 
The evidence from the six clinical trials illustrates the therapeutic benefits that can be 
achieved using topical diclofenac sodium as a key method of pain control for patients 
with OA. Cumulatively the evidence presented by Baer et al, (2005), Roth et al, 
(2004) and Tugwell et al., (2004) convinced the Canadian Arthritis and 
Rheumatology CNW group (2006) to recommend topical diclofenac as the primary 
choice of medication for the management of OA of the knee in patients who are either 
intolerant or sensitive to the actions of oral NSAIDs, or are classified as high risk 
users of oral NSAIDs. Topical diclofenac provides a safe alternative to this select 
group of patients and replaces the use of selective COX-2 inhibitors due to their 
propensity to produce risky side effects such as cardiac arrest and stroke. Topical 
diclofenac is as effective as the maximum daily dose of NSAID and as effective in 
relieving joint stiffness, arthritic pain without the problems of renal, gastric or hepatic 
side effects (Tugwell et al., 2004, Baer et al., 2005, Roth, et al., 2004, Niethard et al., 
2005, Towheed, 2006). Collectively, these studies provide evidence to support the 
chronic use of topical diclofenac sodium in the pain management of OA of the knee. 
 
District nurses with an interest in rheumatology who have non-medical prescribing 
roles should consider the use of topical diclofenac sodium in the pain management of 
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